Mutant KRAS-Driven Tumors: Tissue-Specific Metabolic Rewiring and Microenvironment Influence

Mutant KRAS is a common oncogenic driver in various types of cancer, including pancreatic, colorectal, and lung cancer. It plays a crucial role in promoting tumor growth and progression. Recent studies have highlighted the importance of metabolic reprogramming in cancer cells, and mutant KRAS has been shown to significantly alter cellular metabolism.

However, the metabolic alterations induced by mutant KRAS can vary depending on the tissue of origin and the tumor microenvironment. Tumors arising from different tissues exhibit distinct metabolic profiles, suggesting that tissue-specific factors influence the metabolic rewiring in mutant KRAS-driven tumors.

Pancreatic cancer, for instance, is characterized by a highly glycolytic phenotype, with increased glucose uptake and lactate production. This metabolic shift is driven by mutant KRAS, which activates various signaling pathways, such as the PI3K/AKT/mTOR pathway, leading to increased glucose metabolism. In addition, mutant KRAS promotes glutamine addiction in pancreatic cancer cells, further supporting their metabolic demands.

In contrast, colorectal cancer cells harboring mutant KRAS exhibit a different metabolic phenotype. These cells rely more on fatty acid oxidation (FAO) for energy production, rather than glucose metabolism. Mutant KRAS has been shown to upregulate the expression of key enzymes involved in FAO, such as carnitine palmitoyltransferase 1A (CPT1A), to support this metabolic shift. Moreover, mutant KRAS promotes the uptake of exogenous fatty acids, further fueling FAO in colorectal cancer cells.

The tumor microenvironment also plays a crucial role in shaping the metabolic characteristics of mutant KRAS-driven tumors. The presence of immune cells, such as tumor-associated macrophages (TAMs), can influence the metabolic landscape of the tumor. TAMs, which are often found in the tumor microenvironment, can release cytokines and metabolites that promote tumor growth and alter metabolic pathways in cancer cells. For example, TAM-derived lactate can be taken up by cancer cells and used as a fuel source for oxidative phosphorylation.

Furthermore, the availability of nutrients and oxygen within the tumor microenvironment can impact the metabolic preferences of mutant KRAS-driven tumors. Hypoxic conditions, which are commonly observed in solid tumors, can induce metabolic adaptations, such as increased glycolysis and reduced mitochondrial respiration. These adaptations allow cancer cells to survive and proliferate under low oxygen conditions.

In conclusion, mutant KRAS-driven tumors exhibit tissue-specific metabolic rewiring, with distinct metabolic phenotypes observed in different cancer types. The tumor microenvironment, including immune cells and nutrient availability, further contributes to the metabolic adaptations in these tumors. Understanding the tissue-specific metabolic dependencies and the influence of the microenvironment is crucial for developing effective therapeutic strategies targeting mutant KRAS-driven cancers.